Reloxaliase

DB15560InvestigationalProtein Based Therapies

Reloxaliase is a crystalline formulation of oxalate decarboxylase derived from Bacillus Subtilis. Reloxaliase is under investigation in clinical trial NCT03456830 (Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria).

Mechanism: Pharmacologically active on Oxalate decarboxylase OxdC
Curator reviewed
Code names: ALLN-177

Resolves to

Compound

UNII48OB405WWCCAS202011-67-4

Targets

O34714oxdC

What you can answer from here — as of September 25, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Reloxaliase, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account